talki.com rapport :   Visitez le site

Données techniques du talki.com

Geo IP vous fournit comme la latitude, la longitude et l'ISP (Internet Service Provider) etc. informations. Notre service GeoIP a trouvé l'hôte talki.com.Actuellement, hébergé dans United Kingdom et son fournisseur de services est Datapipe .

the related websites

domaine	Titre
talki.com	boehringer ingelheim - value through innovation
preventionavc.com	boehringer ingelheim - value through innovation

talkiwalki.fr dynamicradio.fr electrocanin.fr cdiscount.com peruwelzfc.be eljadida.canalblog.com assassinat-jfk.com jeuxvideo.com 

Analyse d'en-tête HTTP

Les informations d'en-tête HTTP font partie du protocole HTTP que le navigateur d'un utilisateur envoie à appelé Apache/2.2.15 contenant les détails de ce que le navigateur veut et acceptera de nouveau du serveur Web.

DNS

HtmlToText

-- ") skip to main content information for... please select general use patients or carers health care professionals in the us health care professionals outside the us journalists jobseekers press contact global sites about us corporate profile our company vision & values history diversity & inclusion ethics & compliance sustainability making more health access to healthcare press press releases image mediapool events & initiatives media contacts annual press conference global activities europe north america south america asia africa australasia products innovation research & development research approach research beyond borders drug discovery open innovation clinical trials overview therapeutic areas cardiometabolic cns immunology & respiratory oncology boehringer ingelheim venture fund partnering our approach overview what we offer partnering interests overview how we engage overview news & communications press releases events partnering newsletter contact us human pharma cardiovascular stroke prevention acute ischaemic stroke dvt/pe reversal of anti-coagulation myocardial infarction hypertension oncology lung cancer respiratory asthma copd ipf scleroderma central nervous system overview metabolic diseases diabetes introdia immunology overview animal health home about animal health business unit our responsibility press releases biopharma biosimilars contract manufacturing press releases careers search form search information for... please select general use patients or carers health care professionals in the us health care professionals outside the us journalists jobseekers we passionately improve health boehringer ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. annual report 2017 our company annual report 2017: agility for over 130 years, boehringer ingelheim has continuously undergone change. read more how agility drives us in our annual report 2017. read more on annual report 2017: agility research approach research & development research approach our new discovery research strategy aims at enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. read more on research approach careers working at boehringer ingelheim – being part of a global family as a research-driven pharmaceutical company boehringer ingelheim strives to improve health of people and animals everywhere in the world. read more on working at boehringer ingelheim – being part of a global family - animal health: one business, one vision, one global leader in disease prevention and treatment by bringing together the best minds in the business, boehringer ingelheim and merial have united to create one animal health company with the portfolio, scale and talent to make the industry even better at improving animal health. read more on animal health: one business, one vision, one global leader in disease prevention and treatment therapeutic areas cancer immunology at boehringer ingelheim scientists at boehringer ingelheim are exploring exciting new approaches to turn up the heat on cancer by firing up our immune systems in a tumor-specific manner. read more on cancer immunology at boehringer ingelheim play pause previous next explore our content press release 13 sep 2018 at 08:00 boehringer ingelheim acquires all viratherapeutics shares to develop next generation viral-based immuno-oncology therapies read more on boehringer ingelheim acquires all viratherapeutics shares to develop next generation viral-based immuno-oncology therapies press release 04 sep 2018 at 16:14 boehringer ingelheim launches the first liquid solution for hypertension in cats read more on boehringer ingelheim launches the first liquid solution for hypertension in cats press release 21 aug 2018 at 16:00 new tablet production facility in ingelheim: centerpiece for global launches read more on new tablet production facility in ingelheim: centerpiece for global launches press release 20 aug 2018 at 11:00 development partner boehringer ingelheim supplies clinical material manufactured in china for new cancer drug read more on development partner boehringer ingelheim supplies clinical material manufactured in china for new cancer drug green chemistry sustainability green chemistry green chemistry is indispensable for boehringer ingelheim. with the development of igal, we have taken the lead in developing green chemistry metrics when there was an absence of unified metrics. read more on green chemistry sabine greulich about us “leadership has nothing to do with gender” sabine greulich, country managing director at boehringer ingelheim in italy, is convinced that staff development must be based on performance and leadership competencies. read more on “leadership has nothing to do with gender” press release 01 aug 2018 at 10:00 boehringer ingelheim achieves modest growth in the first half of 2018 read more on boehringer ingelheim achieves modest growth in the first half of 2018 christiane wijsen about us “be courageous!” christiane wijsen, head of pharma france at boehringer ingelheim, reveals her personal experiences and insights on the way to senior management and outlines what she expects of her employer. read more on “be courageous!” home: homepage about us corporate profile careers global activities innovation research clinical trials therapeutic areas boehringer ingelheim venture fund human pharma cardiovascular oncology respiratory central nervous system metabolic diseases immunology business units prescription medicine animal health biopharma global activities africa asia australasia europe north america south america share back to top facebook twitter youtube linkedin instagram pinterest rss accessibility statement terms of use data privacy imprint © 2010-2018 boehringer ingelheim international gmbh. all rights reserved.

Analyse PopURL pour talki.com

https://www.boehringer-ingelheim.com/who-we-are/our-company
https://www.boehringer-ingelheim.com/terms-use
https://www.boehringer-ingelheim.com/innovation/therapeutic-areas/immunology-respiratory
https://www.boehringer-ingelheim.com/innovation
https://www.boehringer-ingelheim.com/partnering/news/partnering-newsletter
https://www.boehringer-ingelheim.com/cardiovascular/dvtpe
https://www.boehringer-ingelheim.com/products
https://www.boehringer-ingelheim.com/locations/europe
https://www.boehringer-ingelheim.com/partnering
https://www.boehringer-ingelheim.com/making-more-health
https://www.boehringer-ingelheim.com/innovation/therapeutic-areas/oncology
https://www.boehringer-ingelheim.com/innovation/research_development/research_approach_overview
https://www.boehringer-ingelheim.com/press-release/first-liquid-solution-hypertension-cats
https://www.boehringer-ingelheim.com/our-company/careers/working-boehringer-ingelheim
https://www.boehringer-ingelheim.com/events-initatives

Informations Whois

Whois est un protocole qui permet d'accéder aux informations d'enregistrement.Vous pouvez atteindre quand le site Web a été enregistré, quand il va expirer, quelles sont les coordonnées du site avec les informations suivantes. En un mot, il comprend ces informations;

Domain Name: TALKI.COM
Registry Domain ID: 21964285_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.corehub.net
Registrar URL: http://corehub.net
Updated Date: 2017-03-08T08:33:13Z
Creation Date: 2000-03-09T12:19:31Z
Registry Expiry Date: 2019-03-09T11:19:31Z
Registrar: Corehub, S.R.L.
Registrar IANA ID: 15
Registrar Abuse Contact Email: abuse@corehub.net
Registrar Abuse Contact Phone: +34935275235
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS2.OBSERVATOIREDESMARQUES.FR
Name Server: NS3.NAMESHIELD.NET
Name Server: OBS.NS1.FR
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-08-20T13:12:09Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR Corehub, S.R.L.

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =talki.com

  PORT 43

  TYPE domain
RegrInfo
DOMAIN

  NAME talki.com

  CHANGED 2017-03-08

  CREATED 2000-03-09

STATUS
clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
clientTransferProhibited https://icann.org/epp#clientTransferProhibited
clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited

NSERVER

  NS2.OBSERVATOIREDESMARQUES.FR 80.74.69.8

  NS3.NAMESHIELD.NET 45.63.17.113

  OBS.NS1.FR 81.92.84.146

  REGISTERED yes

Erreurs

La liste suivante vous montre les fautes d'orthographe possibles des internautes pour le site Web recherché.